Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorry, shouldn't have piggybacked on your comment.
You're telling me this, why?
Apparently but I do not watch the Canadian markets.
Has been for over two, going on three months.
Isn’t it still halted on CSE?
will they take this real or fake opportunity to close all the gaps...?
...is it normal for a halted canadian company to continue to trade on otc...?
When is the halt going to be lifted?
wish the gaps were not left open here...up almost 200 on mind
riding coattails here...clearly not currently as sexy as mmedf or cmps but hard to sort of real value at this juncture...had a double in this and held it..does this have as much potential as the others...??..anyone know next catalyst here...?
Yes. I was buying and selling down to DOW 18,000
What a ride that was!
Not very hard given the current market climate.
You could have bought almost anything in March and pulled a 600%+ profit in less than a quarter, especially in the commodities space.
Dwarfed 566% in about 2 months? Well then, you go get 'em. Crushing it and leaving everyone behind in their dust. Sounds fun!.
Been mutilple moves that dwarfed that in the commodities space that I've been a part of.
I don't feel FOMO when I miss moves in dumpster stocks. Happens literally every day. Can't be everywhere at once.
As long as I'm making money that's all I care about.
I guess you might say that if you missed $0.30 to $1.70
Not even that good of an OTC trade.
There's multiple sub penny pieces of shit that have daily volatility of more than 33% and heavy volume to flip.
OK. This is the second time I have traded this company.
So far 0.30 to 0.40 for a 33% return.
I have plenty of quality positions, but there are some stocks that I know intimately, and when I see a chart opportunity, I take it.
See Charlottes Web.
There’s literally thousands of stocks, with opportunities everywhere. No such thing as missing a trade or fomo to me
Eventually. You may miss another "trade."
I think it’ll touch it again
Never said it was impossible to make money on trash.
Just why would you want to when there's plenty good to buy. Especially in this volatile market.
You had it for a moment.
I have been out of my mind twice, buying previously at 0.30 and recently at 0.30.
Equals BANK.
This trash has been halted in Canada for months with no communication from the company.
You're out of your mind if you buy this.
No, I think they are planning to take it into the 10's.
Maybe tomorrow we pull back a bit more, I’m watching for entry
Looks like thy're planning to take it into the .20's...
I don't know about the business. I like it, but these may be just a trade.
I started buying SHRMF at 0.30
Sold about $1.60
And started buying at 0.30 again.
One of the originals. Take a peek at the CEO.
I like this sector as it reminds me of pre cannabis runups.
Its.a longer term hold.
I am hevy into the other won
Mindmed
But both vill do vell
Serious DD needed here. I am invested here but not a big position as there are way superior companies emerging and my investments are therefore prioritized there. GL.
Another mushvroom pley i see
I stert du dilingence.process
ASK $0.43
I hope it sticks.
Very quiet today!
Where is everyone?
Followers
|
38
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
662
|
Created
|
03/02/20
|
Type
|
Free
|
Moderators |
Patents are the lifeblood of the biotech industry. Biotechnology is one of the most research-intensive industries, with companies in the sector typically investing between 40% and 50% of their revenues in research and development, compared to 13% in pharmaceuticals and 5% in the chemical industry. In many cases, IP rights can actually be the final product.
That's why Champignon Brands' ( SHRM ; SHRMF ) already impressive cache of pharmaceutical patents gives it a leg up in the competitive rush to claim market share in the nascent Psilocybin industry.
Normally, when you do clinical trials, the ideal is to own the resulting IP. Champignon is partnering with the University of Miami and Miller School of Medicine in its research work but will own 100% of the intellectual property, drug discovery, and resultant data.
Its Psilocybin Patent Portfolio will greatly help the company in the commercialization of GMO and vegan certified rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders. Even better: It can license its patented formulations to other companies as it deems fit.
Canada NewsWire
VANCOUVER, BC, Oct. 29, 2020
VANCOUVER, BC, Oct. 29, 2020 /CNW/ - Champignon Brands Inc. ("Champignon" or the "Company") (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) continues to work diligently with the British Columbia Securities Commission (the "Commission") to address the ongoing continuous disclosure review and to coordinate the revocation of the existing cease trade order. The Company will provide guidance on definitive timing for revocation as soon as possible.
The Company has submitted all requested documentation to the Commission in connection with the review of financial statements of AltMed Capital Corp. ("AltMed") for the period ended June 30, 2020, and subject to review by the Commission expects to move forward with the finalization and public filing of these statements in short order.
Continuous Disclosure Review History
On June 19, 2020, the Company was notified by the Commission that it would be subject to a continuous disclosure review. Such reviews are conducted by the Commission for the purposes of ensuring compliance with the continuous disclosure obligations imposed by applicable Canadian securities laws. In the case of the Company, this review relates to the Company's disclosure obligations since it became a reporting issuer on February 6, 2020 and includes a review of the disclosure surrounding acquisitions completed by the Company since that time.
In connection with the review, on June 19, 2020, the Commission issued a cease trade order suspending trading in the securities of the Company pending the filing of Business Acquisition Reports in connection with the acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. As a result of the cease trade order, trading in the common shares of the Company was suspended on the Canadian Securities Exchange.
The Business Acquisition Reports were filed by the Company on July 21, 2020, during which time the Company continued to work with the Commission to address comments received in the course of the disclosure review. As a result of the filing of the Business Acquisition Reports, on August 26, 2020, the Commission revoked the cease trade order previously issued on June 19, 2020. Concurrently with the revocation, the Commission issued a replacement cease trade order (the "Replacement Order"), pending the filing of a revised material change report (the "Material Change Report") in connection with the acquisition by the Company of AltMed.
Prior to the finalization of a revised Material Change Report, the Company is required to finalize the accounting treatment for the acquisition of AltMed, which includes compiling the financial statements of AltMed for the six-month period ended June 30, 2020 to meet disclosure requirements.
On October 27, 2020, the Commission issued an additional cease trade order pending the filing of the interim financial statements of the Company for the period ended June 30, 2020 (the "October Order").
The October Order is not expected to affect the review process or timing for the resumption of trading of the common shares of the Company as the reports required to be filed to satisfy the Replacement Order will address the outstanding items in the October Order.
For further clarity, the Company anticipates that the Replacement Order and the October Order will be revoked at the same time. The Company is working diligently with the Commission to ensure that the revocation of both the Replacement Order and October Order occurs as soon as possible.
Dr. Roger McIntyre
Chief Executive Officer
E: info@champignonbrands.com
FOR INVESTOR INQUIRIES:
Champignon Brands | Storyboard Communications
Investor Relations, Toronto, Canada
Investor Line: +1 (833) 375-9995 x611
E: champignonbrands@storyboardcommunications.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |